Bridgebio Pharma Inc (BBIO) cash flow statement
TrendArc score 42 of 100 · Health 1.7 · Momentum 6.8 · Moat 3.9 · scored Nov 17, 2026 · How the score works
Free cash flow, fiscal year to December 31, 2025
-$447 million
against -$522 million the year before
In the fiscal year to December 2025, Bridgebio Pharma used $446 million in its operations and spent $1 million on capital spending, a free cash flow of -$447 million. That was -89.0% of revenue, against -235.1% the year before. Over the last four quarters, to September 30, 2026, it was -$370 million.
What stands out
- Diluted shares outstanding rose 62.3% over the five fiscal years to December 2025.
Each sentence is written by a fixed rule from the figures on this page.
Free cash flow and net income, the last 9 fiscal years
Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.
Cash flow statement, the last 9 fiscal years
| Fiscal year to | Last 4 quarters to Sep 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | -725 | -536 | -643 | -481 | -563 | -449 | -261 | -131 | -31 | |
| Depreciation and amortisation | 10 | 10 | 11 | 12 | 11 | 5 | 1 | — | — | |
| Stock-based pay | 152 | 133 | 96 | 109 | 92 | 100 | 58 | 21 | 6 | 2 |
| Working capital and other items | 136 | -91 | -4 | -42 | -46 | -14 | -15 | — | — | |
| Cash from operations | -369 | -446 | -521 | -528 | -419 | -498 | -400 | -254 | -137 | -40 |
| Investing activities | ||||||||||
| Capital spending | -1 | -1 | -1 | -1 | 105 | -13 | -8 | -3 | -2 | 0 |
| Businesses bought and sold, net | 0 | 0 | -1 | 10 | 14 | 0 | 0 | -19 | 0 | |
| Investments bought and sold, net | -15 | 70 | 56 | 339 | -166 | -39 | -213 | 0 | 0 | |
| Other investing | -8 | -8 | 0 | -2 | -35 | -7 | -2 | 0 | 0 | |
| Cash from investing | -24 | 61 | 54 | 453 | -201 | -53 | -217 | -21 | 0 | |
| Financing activities | ||||||||||
| Debt issued or repaid, net | 401 | 433 | 0 | -20 | 1,064 | 537 | 37 | 56 | 4 | |
| Shares issued less bought back | -264 | -56 | 312 | 446 | 6 | -201 | -75 | 367 | 96 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other financing | 14 | 4 | 5 | 2 | -126 | -15 | -5 | 350 | 109 | |
| Cash from financing | 359 | 748 | 452 | -13 | 736 | 447 | 399 | 502 | 113 | |
| Net change in cash | -111 | 289 | -22 | 21 | 38 | -6 | -72 | 344 | 72 | |
| Free cash flow | ||||||||||
| Free cash flow | -370 | -447 | -522 | -529 | —a | -511 | -407 | -256 | -139 | -41 |
| Free cash flow margin | -39.1% | -89.0% | -235.1% | -5686.6% | — | -733.2% | -4936.7% | -631.7% | — | — |
| Free cash flow per share | -$2.33 | -$2.80 | -$3.25 | — | -$3.54 | -$3.45 | -$2.44 | -$2.25 | -$1.34 | |
| Free cash flow less stock-based pay | -580 | -617 | -638 | — | -611 | -466 | -278 | -145 | -43 | |
a: capital spending was positive that year (the company sold more property and equipment than it bought), so no free cash flow is shown.
Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.
Bridgebio Pharma against its peers
| Company | Fiscal year to | Free cash flow | Free cash flow margin |
|---|---|---|---|
| ExelixisEXEL | Dec 2025 | $876M | 37.7% |
| RevvityRVTY | Dec 2025 | $509M | 17.8% |
| Charles River LaboratoriesCRL | Dec 2025 | $518M | 12.9% |
| Cooper Companies (The)COO | Oct 2025 | $434M | 10.6% |
| Brightspring Health ServicesBTSG | Dec 2025 | $395M | 3.1% |
| Baxter InternationalBAX | Dec 2025 | $323M | 2.9% |
| SolventumSOLV | Dec 2025 | -$10.0M | -0.1% |
| GlaukosGKOS | Dec 2025 | -$39.1M | -7.7% |
| Bridgebio PharmaBBIO | Dec 2025 | -$447M | -89.0% |
| Peer median | 6.8% |
Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.
Next
Follow Bridgebio Pharma with a free account.
A watchlist, price alerts and saved chart layouts. No card needed.
Sign up freeNo forecast, no recommendation. This page describes Bridgebio Pharma Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.
The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.